This is a multi-center, non-randomized and open-label phase I/IIa clinical study to evaluate the safety, tolerability, and efficacy of ICP-490 in patients with relapsed or refractory non-hodgkin lymphoma.
Aged ≥ 18 years old.
Diagnosed as relapsed or refractory non-hodgkin lymphoma .
The patient must have measurable diseases.
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-2.
Known active central nervous system (CNS) involvement Lymphoma.
Excludes other active malignancies within 3 years before first dose, except locally curable cancers after radical treatment.
Uncontrolled or severe cardiovascular disorders.
Presence or history of clinically significant CNS diseases.